EMA Extends Benefits Of Reduced Parallel Distribution Fee To Estonia, Slovenia
Executive Summary
Estonia and Slovenia have been accepted onto an ongoing initiative by the European Medicines Agency that aims to boost the availability of centrally authorized drugs in smaller member states by charging companies a reduced fee for parallel distribution of medicines.
You may also be interested in...
EMA Reduces Parallel Distribution Fees For Malta & Latvia To Improve Medicines Availability
The European Medicines Agency is charging a reduced fee for parallel distribution of centrally authorized medicines to smaller EU member states under a new initiative that aims to improve the availability of medicines. Malta and Latvia have joined in, and two other member states have showed interest in the initiative, which will end in July 2018.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.